OncoSil Marks First Treatment at Major Berlin Hospital as German Expansion Gathers Pace

OncoSil Medical Ltd ( (AU:OSL) ) has provided an update.

OncoSil Medical has announced the first successful OncoSil™ treatment at Vivantes Neukölln Hospital in Berlin, one of the largest hospitals in Germany and a leading centre for gastrointestinal oncology within the country’s largest municipal hospital group. The hospital is the second in Germany to adopt the OncoSil™ device, marking a key milestone in the company’s expansion in a strategically important market with a high incidence of pancreatic cancer and a strong network of tertiary referral centres. The new site reinforces growing clinical interest in the therapy, supports OncoSil’s strategy to build clinical momentum and physician awareness ahead of an upcoming German reimbursement trial, and is expected to accelerate adoption across Germany and the wider European region.

The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.76 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.

More about OncoSil Medical Ltd

OncoSil Medical Limited is an Australian-listed global medical device company specialising in interventional oncology, with a focus on localised treatments for unresectable locally advanced pancreatic cancer. Its core product, the OncoSil™ device, uses targeted intratumoural placement of Phosphorous-32 microparticles alongside chemotherapy to deliver higher radiation doses directly into pancreatic tumours while minimising exposure to surrounding organs. The device holds CE Marking and breakthrough device designation in Europe and the United States and is approved in more than 30 countries, with commercial use already established across multiple European markets, Turkey, Israel and the UK.

Average Trading Volume: 23,032

Technical Sentiment Signal: Sell

Current Market Cap: A$14.36M

For detailed information about OSL stock, go to TipRanks’ Stock Analysis page.